CalciMedica, Inc. (CALC) 10-Year Financial Performance & Capital Metrics

CALC • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutCalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.Show more

Revenue $0
EBITDA -$24M +36.5%
Net Income -$14M +60.1%
EPS (Diluted) -1.22 +84.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -121.42% +71.2%
ROIC -398.88%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 95 (top 5%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-69.71%

EPS CAGR

10Y-

5Y-

3Y-

TTM-2.74%

ROCE

10Y Avg-270.42%

5Y Avg-293.94%

3Y Avg-458.76%

Latest-199.48%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	175K	303K	395K	519K	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	-175K	-303K	-395K	-519K	0	0	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-0.73%	-0.3%	-0.31%	1%	-	-
Operating Expenses+	28.57M	37.2M	29.44M	35.43M	14.19M	38.08M	24.2M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	5.6M	6.62M	8.87M	17.04M	5.84M	22.22M	9.73M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	22.97M	30.58M	20.96M	18.9M	8.35M	15.86M	14.48M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	-395K	-519K	0	0	0
Operating Income+	-28.57M	-37.5M	-29.83M	-35.95M	-14.19M	-38.08M	-24.2M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.31%	0.2%	-0.2%	0.61%	-1.68%	0.36%
EBITDA+	-28.39M	-37.2M	-29.44M	-35.43M	-14.14M	-38.02M	-24.15M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.31%	0.21%	-0.2%	0.6%	-1.69%	0.36%
D&A (Non-Cash Add-back)	175K	303K	395K	519K	52K	58K	58K
EBIT	-28.38M	-37.04M	-27.53M	-35.82M	-7.69M	-38.08M	-24.2M
Net Interest Income+	0	393K	0	0	-132K	-110K	0
Interest Income	192K	393K	143K	126K	0	0	0
Interest Expense	0	0	143K	126K	132K	110K	0
Other Income/Expense	192K	465K	2.3M	126K	6.37M	3.72M	10.5M
Pretax Income+	-28.38M	-37.04M	-27.53M	-35.82M	-7.82M	-34.36M	-13.7M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	13.86K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-28.38M	-37.04M	-27.53M	-35.82M	-7.82M	-34.36M	-13.7M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-0.31%	0.26%	-0.3%	0.78%	-3.39%	0.6%
Net Income (Continuing)	-28.38M	-37.04M	-27.53M	-35.82M	-7.82M	-34.36M	-13.7M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-33.10	-35.85	-73.50	-23.66	-23.20	-7.65	-1.22
EPS Growth %	-	-0.08%	-1.05%	0.68%	0.02%	0.67%	0.84%
EPS (Basic)	-33.10	-35.85	-73.50	-23.66	-23.20	-7.65	-1.22
Diluted Shares Outstanding	857.28K	1.03M	472.75K	1.51M	1.53M	4.49M	11.25M
Basic Shares Outstanding	857.28K	1.03M	472.75K	1.51M	1.53M	4.49M	11.25M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	13.45M	36.27M	99.24M	67.08M	1.73M	11.61M	19.66M
Cash & Short-Term Investments	12.83M	35.96M	95.03M	63.67M	1.33M	11.24M	18.67M
Cash Only	12.83M	15.87M	33.42M	13.36M	1.33M	5.53M	7.93M
Short-Term Investments	0	20.09M	61.62M	50.31M	0	5.71M	10.73M
Accounts Receivable	0	0	0	21K	39K	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	-21K	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	0	1.37M	-139K	296K	248K
Total Non-Current Assets+	4.37M	4.39M	2.55M	2.01M	1.62M	580K	129K
Property, Plant & Equipment	1.51M	1.98M	1.95M	1.98M	195K	167K	119K
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	28K	28K	0	0	0	0	0
Other Non-Current Assets	2.83M	2.39M	608K	29K	1.42M	413K	10K
Total Assets+	17.81M	40.66M	101.79M	69.09M	3.35M	12.19M	19.79M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	1.28%	1.5%	-0.32%	-0.95%	2.64%	0.62%
Total Current Liabilities+	5.79M	12.25M	7M	4.06M	4.78M	4.03M	3.68M
Accounts Payable	2.52M	4.64M	2.51M	527K	2.87M	1.42M	2M
Days Payables Outstanding	5.26K	5.58K	2.32K	370.63	-	-	-
Short-Term Debt	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	8K	0	0	0
Other Current Liabilities	2.04M	5.57M	826K	1.24M	-4K	89K	1.16M
Current Ratio	2.32x	2.96x	14.18x	16.53x	0.36x	2.88x	5.34x
Quick Ratio	2.32x	2.96x	14.18x	16.54x	0.36x	2.88x	5.34x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	78.81M	131.36M	11K	8K	7.8M	0	1.7M
Long-Term Debt	0	0	0	0	5.16M	0	0
Capital Lease Obligations	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	11K	0	2.65M	0	1.7M
Total Liabilities	5.79M	12.25M	7.01M	4.07M	12.58M	4.03M	5.38M
Total Debt+	78.81M	131.36M	0	0	5.36M	0	0
Net Debt	65.98M	115.49M	-33.42M	-13.36M	4.03M	-5.53M	-7.93M
Debt / Equity	6.56x	4.62x	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-208.62x	-285.29x	-107.52x	-346.14x	-
Total Equity+	12.02M	28.41M	94.79M	65.02M	-9.23M	8.16M	14.41M
Equity Growth %	-	1.36%	2.34%	-0.31%	-1.14%	1.88%	0.77%
Book Value per Share	14.02	27.50	200.50	42.94	-6.02	1.82	1.28
Total Shareholders' Equity	12.02M	28.41M	94.79M	65.02M	-9.23M	8.16M	14.41M
Common Stock	1K	1K	2K	2K	1K	1K	4K
Retained Earnings	-68.8M	-105.84M	-133.37M	-169.19M	-111.71M	-146.06M	-159.76M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-1K	3K	-4K	-16K	-37K	2K	4K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-28.22M	-31.21M	-32.06M	-31.5M	-11.76M	-25.73M	-21.15M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.11%	-0.03%	0.02%	0.63%	-1.19%	0.18%
Net Income	-28.38M	-37.04M	-27.53M	-35.82M	-7.82M	-34.36M	-13.7M
Depreciation & Amortization	175K	303K	395K	519K	52K	58K	58K
Stock-Based Compensation	348K	738K	1.79M	5.38M	1.81M	12.04M	2.31M
Deferred Taxes	0	0	1K	0	0	-3.31M	0
Other Non-Cash Items	18K	-140K	-2.16M	58K	-6.4M	110K	-9.32M
Working Capital Changes	-379K	4.92M	-4.56M	-1.63M	605K	-267K	-495K
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	1.37M	1.4M	-1.46M	-2.05M	933K	-1.43M	601K
Cash from Investing+	-1.46M	-20.62M	-42.56M	10.75M	-4K	8.88M	-4.42M
Capital Expenditures	-1.46M	-605K	-1.02M	-488K	-4K	-78K	-8K
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	42.02M	54.87M	92.17M	695K	8.48M	20.9M	27.97M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	124K	89K	-4.08M	0	0	-4.54M	20K
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-29.68M	-31.82M	-33.09M	-31.99M	-11.76M	-25.81M	-21.15M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-0.07%	-0.04%	0.03%	0.63%	-1.19%	0.18%
FCF per Share	-34.62	-30.80	-69.99	-21.12	-7.66	-5.75	-1.88
FCF Conversion (FCF/Net Income)	0.99x	0.84x	1.16x	0.88x	1.50x	0.75x	1.54x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-236.11%	-183.22%	-44.7%	-44.83%	-28.05%	-421.2%	-121.42%
Return on Invested Capital (ROIC)	-27.47%	-25.35%	-21.8%	-47.71%	-45.82%	-	-398.88%
Debt / Equity	6.56x	4.62x	-	-	-	-	-
Interest Coverage	-	-	-208.62x	-285.29x	-107.52x	-346.14x	-
FCF Conversion	0.99x	0.84x	1.16x	0.88x	1.50x	0.75x	1.54x

Frequently Asked Questions

Growth & Financials

CalciMedica, Inc. (CALC) grew revenue by 0.0% over the past year. Growth has been modest.

CalciMedica, Inc. (CALC) reported a net loss of $23.1M for fiscal year 2024.

Dividend & Returns

CalciMedica, Inc. (CALC) has a return on equity (ROE) of -121.4%. Negative ROE indicates the company is unprofitable.

CalciMedica, Inc. (CALC) had negative free cash flow of $21.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener